Lexicon Pharmaceuticals reported $99.51M in Debt for its fiscal quarter ending in December of 2023.





Debt Change Date
Abbott USD 34.05B 20.19B Mar/2026
Acadia Pharmaceuticals USD 73.85M 23.06M Jun/2026
Agios Pharmaceuticals USD 31.17M 4.57M Jun/2026
Akebia Therapeutics USD 46.51M 7.82M Mar/2025
Alnylam Pharmaceuticals USD 2.48B 1.21B Sep/2026
AstraZeneca USD 32.24B 1.68B Jun/2026
BioMarin Pharmaceutical USD 4.19B 11.99M Sep/2026
Coherus Biosciences USD 294.92M 1.25M Mar/2025
Eli Lilly USD 54.91B 11.54B Jun/2026
Halozyme Therapeutics USD 2.15B 2.02M Jun/2026
Illumina USD 2.54B 9M Mar/2026
Insmed USD 544.86M 180.93M Sep/2026
Ironwood Pharmaceuticals USD 583.99M 14.83M Dec/2024
J&J USD 49.04B 5.95B Jun/2026
Lexicon Pharmaceuticals USD 99.51M 243K Dec/2023
MacroGenics USD 35.09M 1.42M Jun/2026
MannKind USD 330.85M 112K Jun/2026
Merck USD 53.91B 4.79B Jun/2026
Moderna USD 1.29B 11M Jun/2026
Novartis USD 49.01B 2.02B Jun/2026
PTC Therapeutics USD 2.84B 2.15B Sep/2026
Puma Biotechnology USD 89.06M 55.07M Jun/2024
Sarepta Therapeutics USD 857.36M 188.48M Sep/2026
Thermo Fisher Scientific USD 42.55B 612M Jun/2026
Ultragenyx Pharmaceutical USD 36M 2.17M Dec/2025
United Therapeutics USD 200M 100M Mar/2025
Vanda Pharmaceuticals USD 4.96M 4.96M Dec/2024